1. | dsau1268 | |
2. | markmcginty13116 | |
3. | StockCats12 | |
4. | michaelj67 | |
5. | DontGiveMeLip |
1. | dsau1268 | |
2. | markmcginty13116 | |
3. | StockCats12 | |
4. | michaelj67 | |
5. | DontGiveMeLip |
1. | DontGiveMeLip 10/18/2017 I don't think many people realize what this is worth if it works. |
2. | StockCats12 10/18/2017 {Image} |
3. | dsau1268 04/04/2018 What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening |
4. | StockCats12 03/01/2018 Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results |
5. | eddiebaez 03/05/2018 Oppenheimer Has a New Play for Biotech Fans: Conatus Pharmaceuticals Inc (CNAT) |
6. | ghp9345 04/05/2018 Conatus Pharmaceuticals (CNAT): Oppenheimer Advises Investors to Wait for the Next Catalyst |
7. | DontGiveMeLip 03/09/2018 Conatus Pharmaceuticals Inc (CNAT): Analyst Looks Forward to "Large Catalysts" Lying Ahead |
8. | ghp9345 04/04/2018 Company reports top-line results from phase 2b POLT-HCV-SVR clinical trial; biopsy-based proof of concept in… |
9. | StockCats12 10/18/2017 $CNAT When you compare market cap of $MDGL ~600M with just phase 2 proof of concept study for NASH...CNAT should be higher than ~160M Good pipeline and A1 science but needs to prove it so might take a |
10. | michaelj67 02/08/2018 Roth Capital initiates |